1. Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial 
Anna S.F. Lok, James E. Everhart, Raymond T. Chung, Latha Padmanabhan, Joel K. Greenson, Mitchell L. Shiffman, Gregory T. Everson, Karen L. Lindsay, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Timothy R. Morgan, Marc G. Ghany, Chihiro Morishima 
Clinical Gastroenterology and Hepatology 
Volume 5, Issue 2, Pages (February 2007)
DOI: /j.cgh
Copyright © 2007 AGA Institute Terms and Conditions

2. Figure 1
Distribution of steatosis scores among nondiabetic (■) and diabetic (□) patients. Hepatic steatosis was graded as follows: 0 (<1%), 1 (1%–5%), 2 (6%–33%), 3 (34%–67%), and 4 (>67%).
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

3. Figure 2
Frequency of cirrhosis in relation to steatosis scores (all patients). Hepatic steatosis was graded as follows: 0 (<1%), 1 (1%–5%), 2 (6%–33%), 3 (34%–67%), and 4 (>67%).
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions